HC Wainwright Has Negative Outlook for NovoCure Q1 Earnings

NovoCure Limited (NASDAQ:NVCR) – Research analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for NovoCure in a research note issued on Thursday, February 5th. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.62) EPS and FY2028 earnings at ($0.35) EPS.

Several other research analysts have also recently issued reports on NVCR. Evercore set a $20.00 target price on shares of NovoCure in a report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. JPMorgan Chase & Co. lowered their price objective on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Monday, October 27th. Finally, Wedbush reiterated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research note on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $25.50.

NovoCure Stock Performance

Shares of NVCR stock opened at $10.03 on Monday. NovoCure has a one year low of $9.82 and a one year high of $22.95. The company’s 50-day moving average is $12.92 and its 200 day moving average is $12.63. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.23 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVCR. AQR Capital Management LLC raised its stake in NovoCure by 56.7% during the 1st quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock valued at $512,000 after buying an additional 10,394 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of NovoCure by 5.5% in the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock worth $17,707,000 after acquiring an additional 52,180 shares during the period. Acadian Asset Management LLC purchased a new stake in NovoCure during the first quarter valued at $87,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in NovoCure by 17.1% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,307 shares of the medical equipment provider’s stock valued at $77,000 after acquiring an additional 629 shares during the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.